Home NASDAQ: AMGN
265.52
price up icon0.47%   +1.25
after-market After Hours: 266.00 0.48 +0.18%
loading
AMGEN Inc. (AMGN) current stock price is $265.52 with a 24-hour trading volume of 1.75M. The stock increased by +0.47% in the last 24 hours and rose by +1.51% in the past month. Looking at the chart, AMGN stock price is above the pivot point level of $263.8, suggesting a potential bullish market, if it continues to reach close to the resistance level of $266.0, significant changes may happen. Moreover, exploring the underlying reasons why AMGN is dropping is crucial for acquiring comprehensive view about the stock. AMGEN Inc. (AMGN) stock has undergone a total of 5 stock splits since its initial public offering which has affected the stock’s price and liquidity.

AMGEN Inc. Stock (AMGN) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

Earnings per Share

loading

AMGEN Inc. Stock (AMGN) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Graham Jonathan P
EVP, Gen. Counsel & Secy.
Nov 08
Sale
272.81
10,000
2,728,136
28,078
AMGEN INC
10% Owner
Sep 19
Buy
17.00
1,764,705
29,999,985
35,368,653
Gordon Murdo
EVP, Global Commercial Ops
Aug 10
Sale
262.43
9,558
2,508,306
44,308
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine. Its products also comprise Blincyto to treat patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia; Kyprolis, a proteasome inhibitor for the treatment of multiple myeloma and small-cell lung cancer; Nplate, a thrombopoietic compound. The company's marketed products include Neulasta, a pegylated protein to treat cancer patients; Aranesp to treat anemia; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; EPOGEN to treat a lower-than-normal number of red blood cells; NEUPOGEN, a recombinant human granulocyte colony-stimulating factor; and IMLYGIC to treat various cancer cells. It serves pharmaceutical wholesale distributors; and physicians or their clinics, dialysis centers, hospitals, and pharmacies, as well as consumers. The company has collaborative agreements with Pfizer Inc.; UCB; Bayer HealthCare Pharmaceuticals Inc.; The University of Texas MD Anderson Cancer Center, and Provention Bio, Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
drug_manufacturers_general SNY
$46.98
price down icon 1.41%
drug_manufacturers_general PFE
$29.69
price down icon 1.49%
drug_manufacturers_general BMY
$48.92
price down icon 0.20%
$74.51
price down icon 0.55%
drug_manufacturers_general NVS
$97.00
price down icon 0.76%
Cap:     |  Volume (24h):